TABLE 5.
Reference | No. Patients | Prior anti-TNF exposure (n, %) | Clinical response (n, %) | Endoscopic response (n, %) |
---|---|---|---|---|
Bar et al. 18 | 20 | 11 (55) | 13 (65) | 9 (64.3) |
Khan et al. 21 | 12 | 8 (66.7) | 8 (66.7) | 10 (83.3) |
Philpott et al. 12 | 4 | 4 (100) | 4 (100) | 4 (100) |
Shelton et al. 13 | 8a | Not reported | 6 (75) | Not reported |
Coletta et al. 16 | 1 | 1 (100) | 1 (100) | 1 (100) |
Bethge et al. 17 | 1 | 1 (100) | 1 (100) | 1 (100) |
Schmid et al. 15 | 1 | 0 (0) | 1 (100) | 1 (100) |
aAn additional patient with pouchitis was treated with vedolizumab but did not have efficacy data.